Prof. Santos part of a major European initiative funded under the Innovative Health Initiative (IHI)
➡️ Bringing together 42 partners, the project aims to transform cardiovascular care through earlier detection, personalized interventions, and more equitable access, ultimately reducing health inequalities across Europe.
➡️ Coordinated by UMCG research under the leadership of Prof. Pim van der Harst, EXIT‑CVD started on 1 April 2026 with a total budget of €27.67 million. This initiative represents a significant step forward in advancing sustainable, high‑impact cardiovascular health.
➡️ Prof. Santos is participating in the sub-project representing the Department of Biomaterials and Biomedical Technology, where together with AstraZeneca the focus is on accelerating the clinical integration of innovative therapies, such as the next‑generation RNA‑based cardiac drug delivery.
➡️ EXIT‑CVD is an inspiring collaboration of universities, hospitals, research institutes, and industry partners, all united by the mission to improve outcomes for patients living with cardiovascular disease.
More information at https://www.ihi.europa.eu/projects-results/project-factsheets/exit-cvd and https://cordis.europa.eu/project/id/101253160
